Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
2-oxoisovalerate dehydrogenase subunit beta, mitochondrial (BCKDHB) is a vital component of the E1 subunit within the branched-chain alpha-keto acid dehydrogenase (BCKDH) complex. This mitochondrial enzyme complex is responsible for the rate-limiting step in the catabolism of branched-chain amino acids (BCAAs), specifically leucine, isoleucine, and valine [UniProt: P21953]. BCKDHB works in conjunction with the alpha subunit to perform the thiamine pyrophosphate-dependent oxidative decarboxylation of alpha-keto acids derived from BCAAs [PubMed: 11555028]. Mutations in the BCKDHB gene lead to Maple Syrup Urine Disease (MSUD) type 1B, a condition characterized by the toxic accumulation of BCAAs and their keto acid derivatives, which can lead to severe neurological damage and metabolic crisis [NIH: Genetic and Rare Diseases Information Center]. While not a traditional target for inhibitory drugs, BCKDHB is a focus for therapeutic modulation; for example, thiamine is used as a cofactor to boost residual enzyme activity in certain MSUD phenotypes [PubMed: 25533354]. Additionally, sodium phenylbutyrate is employed to indirectly enhance the activity of this subunit by inhibiting the regulatory kinase that normally inactivates the BCKDH complex [PubMed: 21304891]. Current research also explores the use of pharmacological chaperones and gene therapy to restore the functional integrity of the BCKDHB subunit in affected patients [PubMed: 29127304].
Thiamine serves as a required cofactor for the E1 subunit, facilitating the oxidative decarboxylation of branched-chain alpha-keto acids [PubMed: 25533354]. Sodium phenylbutyrate acts as an indirect activator by inhibiting BCKDH kinase (BCKDK), which prevents the phosphorylation-mediated inactivation of the BCKDH complex, thereby increasing the net activity of the beta subunit and its associated complex [PubMed: 21304891].
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 2-oxoisovalerate dehydrogenase subunit beta, mitochondrial (BCKDHB).